在造血细胞中表位碱基编辑 CD45 以实现通用血液肿瘤免疫治疗
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy
血液肿瘤缺乏特异性表面抗原，现有免疫疗法只能针对少数谱系抗原，且需逐一设计，效率低下。研究人员尝试开发靶向泛白细胞标志物 CD45 的通用 CAR T 细胞疗法。为保护健康造血细胞免受 CD45 靶向的误伤，他们定位了 CAR 识别的 CD45 表位，并用 CRISPR 腺嘌呤碱基编辑引入一个保留 CD45 功能但能逃逸 CAR 识别的突变。表位编辑后的 CD45 CAR T 细胞不会自相残杀，且对来自患者的急性髓系白血病、B 细胞淋巴瘤和急性 T 细胞白血病均有效。表位编辑的造血干细胞能抵抗 CAR T 细胞攻击，并在体内成功植入、存活和分化。该策略有望实现安全、通用的血液肿瘤免疫治疗。
为什么推荐给您：表位碱基编辑加 CD45 靶向的通用 CAR T 策略为全新治疗范式，但尚属体外及动物水平验证。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
In the absence of cell surface cancer-specific antigens, immunotherapies such as chimeric antigen receptor (CAR) T cells, monoclonal antibodies, or bispecific T cell engagers typically target lineage antigens. Currently, such immunotherapies are individually designed and tested for each disease. This approach is inefficient and limited to a few lineage antigens for which the on-target/off-tumor toxicities are clinically tolerated. Here, we sought to develop a universal CAR T cell therapy for blood cancers directed against the pan-leukocyte marker CD45. To protect healthy hematopoietic cells, including CAR T cells, from CD45-directed on-target/off-tumor toxicity while preserving the essential functions of CD45, we mapped the epitope on CD45 that is targeted by the CAR and used CRISPR adenine base editing to install a function-preserving mutation sufficient to evade CAR T cell recognition. Epitope-edited CD45 CAR T cells were fratricide resistant and effective against patient-derived acute myeloid leukemia, B cell lymphoma, and acute T cell leukemia. Epitope-edited hematopoietic stem cells (HSCs) were protected from CAR T cells and, unlike CD45 knockout cells, could engraft, persist, and differentiate in vivo. Ex vivo epitope editing in HSCs and T cells enables the safe and effective use of CD45-directed CAR T cells and bispecific T cell engagers for the universal treatment of hematologic malignancies and might be exploited for other diseases requiring intensive hematopoietic ablation.